 Kallikreins
"Kallikreins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77).
| Descriptor ID |
D007610
|
| MeSH Number(s) |
D08.811.277.656.300.760.442 D08.811.277.656.959.350.442 D12.776.124.125.597 D23.119.597
|
| Concept/Terms |
Kallikreins- Kallikreins
- Kalliginogenase
- Kallikrein
- Kininogenase
- Callicrein
- Kallidinogenase
- Kinin-Forming Enzyme
- Enzyme, Kinin-Forming
- Kinin Forming Enzyme
|
Below are MeSH descriptors whose meaning is more general than "Kallikreins".
Below are MeSH descriptors whose meaning is more specific than "Kallikreins".
This graph shows the total number of publications written about "Kallikreins" by people in this website by year, and whether "Kallikreins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 | | 2012 | 1 | 1 | 2 | | 2014 | 0 | 1 | 1 | | 2015 | 1 | 2 | 3 | | 2016 | 1 | 1 | 2 | | 2017 | 0 | 1 | 1 | | 2018 | 0 | 3 | 3 | | 2019 | 0 | 1 | 1 | | 2020 | 0 | 2 | 2 | | 2021 | 2 | 0 | 2 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Kallikreins" by people in Profiles.
-
Pignolo RJ, McCarrick-Walmsley R, Wang H, Qiu S, Hunter J, Barr S, He K, Zhang H, Kaplan FS. Plasma-Soluble Biomarkers for Fibrodysplasia Ossificans Progressiva (FOP) Reflect Acute and Chronic Inflammatory States. J Bone Miner Res. 2022 03; 37(3):475-483.
-
Hanamura T, Christenson JL, O'Neill KI, Rosas E, Spoelstra NS, Williams MM, Richer JK. Secreted indicators of androgen receptor activity in breast cancer pre-clinical models. Breast Cancer Res. 2021 11 04; 23(1):102.
-
Pickles K, Scherer LD, Cvejic E, Hersch J, Barratt A, McCaffery KJ. Preferences for More or Less Health Care and Association With Health Literacy of Men Eligible for Prostate-Specific Antigen Screening in Australia. JAMA Netw Open. 2021 10 01; 4(10):e2128380.
-
Shahangian S, Sharma KP, Fan L, Siegel DA. Use of the prostate-specific antigen test in the U.S. for men age 30 to 64 in 2011 to 2017 using a large commercial claims database: Implications for practice interventions. Cancer Rep (Hoboken). 2021 08; 4(4):e1365.
-
Shahangian S, Fan L, Sharma KP, Siegel DA. Use of the prostate-specific antigen (PSA) test in the United States for men age =65, 1999-2015: Implications for practice interventions. Cancer Rep (Hoboken). 2021 08; 4(4):e1352.
-
Cheng TC, Philip JL, Tabima DM, Kumari S, Yakubov B, Frump AL, Hacker TA, Bellofiore A, Li R, Sun X, Goss KN, Lahm T, Chesler NC. Estrogen receptor-a prevents right ventricular diastolic dysfunction and fibrosis in female rats. Am J Physiol Heart Circ Physiol. 2020 12 01; 319(6):H1459-H1473.
-
Barqawi A, Pessoa RR, Al-Musawi M, MacDermott T, O'Donnell CI. The Impact of Performing a 3D Mapping Biopsy Prior to Primary Cryotherapy for the Treatment of Prostate Cancer. Urology. 2020 10; 144:171-176.
-
Seydafkan S, Michl J, Pincus MR. Unique Features of Prostate Cancer in African American and West Indian Patients Including Diagnosis of High Grade Cancers Using Only Elevated Serum Levels of Prostate Specific Antigen. Ann Clin Lab Sci. 2020 Jul; 50(4):504-511.
-
Heath E, Heilbrun L, Mannuel H, Liu G, Lara P, Monk JP, Flaig T, Zurita A, Mack P, Vaishampayan U, Stella P, Smith D, Bolton S, Hussain A, Al-Janadi A, Silbiger D, Usman M, Ivy SP. Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer. Oncologist. 2019 09; 24(9):1149-e807.
-
Miller DR, Ingersoll MA, Chatterjee A, Baker B, Shrishrimal S, Kosmacek EA, Zhu Y, Cheng PW, Oberley-Deegan RE, Lin MF. p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance. Free Radic Biol Med. 2019 08 01; 139:24-34.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|